Mass. cancer drugmaker targets $125M from stock, options sale

07/12/2013 | American City Business Journals

Merrimack Pharmaceuticals could raise $125 million through stock offering and sale of convertible senior notes. The Cambridge, Mass.-based firm will mainly use the proceeds to support clinical studies, regulatory submissions and pre-approval commercial work for MM-398, its experimental drug for metastatic pancreatic cancer.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX